Dyadic International, Inc. reported a significant decline in its financial performance for the fiscal year ending December 31, 2025, with total revenue of $3.09 million, down from $3.50 million in 2024. The decrease was primarily driven by a reduction in research and development revenue, which fell to $967,311 from $1.61 million the previous year. The company also experienced a notable drop in license and milestone revenue, which decreased to $265,000 from $1.89 million. Despite these challenges, Dyadic secured $1.86 million in grant revenue, marking its first recognition of such income, attributed to funding from the Gates Foundation and CEPI.
The company's net loss for 2025 increased to $7.36 million, compared to a loss of $5.81 million in 2024. This rise in losses was largely due to decreased licensing revenue and increased research and development expenses, which rose to $2.16 million from $2.04 million. General and administrative expenses also saw a slight decrease, reflecting cost management efforts. As of December 31, 2025, Dyadic reported an accumulated deficit of approximately $93.5 million, highlighting ongoing financial challenges.
Strategically, Dyadic has been transitioning from a research-focused organization to a commercially driven enterprise, emphasizing the commercialization of its proprietary C1 and Dapibus™ protein production platforms. The company has made strides in product development, including the launch of AlbuFree™ DX recombinant human albumin and recombinant DNase I, which are now available for research applications. Additionally, Dyadic has expanded its collaborations, including a significant agreement with Inzymes ApS for the commercialization of non-animal dairy enzymes.
Operationally, Dyadic's customer base has contracted, with revenue generated from 14 customers in 2025 compared to 19 in 2024. The company continues to rely heavily on a small number of significant customers, with two customers accounting for approximately 60.1% of total revenue in 2025. The company’s workforce remains minimal, with only five full-time employees as of year-end. Looking ahead, Dyadic anticipates continued investment in its research and development efforts, particularly in the biopharmaceutical sector, while also seeking to expand its market presence in non-pharmaceutical applications. The company’s future performance will depend on its ability to secure additional funding and successfully commercialize its product pipeline.
About DYADIC INTERNATIONAL INC
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.